Simulations Plus, Inc. (NASDAQ:SLP – Get Free Report) reached a new 52-week low during mid-day trading on Wednesday after KeyCorp lowered their price target on the stock from $40.00 to $35.00. KeyCorp currently has an overweight rating on the stock. Simulations Plus traded as low as $26.51 and last traded at $26.51, with a volume of 24606 shares changing hands. The stock had previously closed at $30.39.
Other equities research analysts also recently issued research reports about the company. StockNews.com downgraded Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. Stephens initiated coverage on Simulations Plus in a research report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target on the stock. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Wednesday. Finally, BTIG Research decreased their target price on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $49.00.
Get Our Latest Stock Report on Simulations Plus
Insiders Place Their Bets
Institutional Investors Weigh In On Simulations Plus
A number of institutional investors have recently modified their holdings of SLP. Arizona State Retirement System acquired a new stake in shares of Simulations Plus during the 2nd quarter worth approximately $218,000. Los Angeles Capital Management LLC acquired a new position in shares of Simulations Plus during the second quarter valued at about $206,000. Wedbush Securities Inc. raised its stake in Simulations Plus by 10.5% during the 2nd quarter. Wedbush Securities Inc. now owns 18,025 shares of the technology company’s stock worth $876,000 after buying an additional 1,709 shares during the period. Envestnet Asset Management Inc. increased its holdings in shares of Simulations Plus by 1.5% during the second quarter. Envestnet Asset Management Inc. now owns 54,813 shares of the technology company’s stock valued at $2,665,000 after acquiring an additional 784 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Simulations Plus by 10.1% in the second quarter. Dimensional Fund Advisors LP now owns 414,005 shares of the technology company’s stock valued at $20,128,000 after buying an additional 37,992 shares in the last quarter. 78.08% of the stock is owned by institutional investors.
Simulations Plus Price Performance
The stock has a fifty day moving average price of $29.81 and a two-hundred day moving average price of $33.96. The company has a market cap of $566.60 million, a P/E ratio of 57.57 and a beta of 0.80.
Simulations Plus (NASDAQ:SLP – Get Free Report) last posted its earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The firm had revenue of $18.70 million during the quarter, compared to analyst estimates of $19.73 million. During the same quarter in the prior year, the business posted $0.18 EPS. The business’s revenue was up 19.9% compared to the same quarter last year. Equities analysts predict that Simulations Plus, Inc. will post 1.1 earnings per share for the current fiscal year.
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Further Reading
- Five stocks we like better than Simulations Plus
- There Are Different Types of Stock To Invest In
- 3 EV Stocks Offering Unique Alternatives to Tesla
- Why Are Stock Sectors Important to Successful Investing?
- 3 Stocks Leveraging NVIDIA’s Strength for Profits
- 3 REITs to Buy and Hold for the Long Term
- Walgreens Stock Poised for a Rebound: Why Analysts Are Bullish
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.